{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:20:29Z","timestamp":1784906429737,"version":"3.55.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["316803389"],"award-info":[{"award-number":["316803389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1280 (TP A18"],"award-info":[{"award-number":["SFB 1280 (TP A18"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.neuropharm.2020.108424","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T20:22:33Z","timestamp":1607113353000},"page":"108424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor rapamycin"],"prefix":"10.1016","volume":"184","author":[{"given":"Meike","family":"Unteroberd\u00f6rster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Herring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Bendix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"L\u00fcckemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Petschulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Hetze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Schedlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hadamitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108424_bib1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00213-014-3745-5","article-title":"Behavioral effects of nicotinic antagonist mecamylamine in a rat model of depression: prefrontal cortex level of BDNF protein and monoaminergic neurotransmitters","volume":"232","author":"Aboul-Fotouh","year":"2015","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2020.108424_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1677\/JOE-08-0509","article-title":"Acute or chronic stress induce cell compartment-specific phosphorylation of glucocorticoid receptor and alter its transcriptional activity in Wistar rat brain","volume":"202","author":"Adzic","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib3","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1073\/pnas.0912344107","article-title":"Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production","volume":"107","author":"Alain","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108424_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/jir.1998.18.87","article-title":"IFN-beta partially counteracts inhibition of natural killer activity induced by some antitumor agents","volume":"18","author":"Allavena","year":"1998","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/npp.2017.260","article-title":"Too depressed to swim or too afraid to stop? A reinterpretation of the forced swim test as a measure of anxiety-like behavior","volume":"43","author":"Anyan","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108424_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.brainres.2012.11.044","article-title":"Rapamycin inhibits the growth of glioblastoma","volume":"1495","author":"Arcella","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib7","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1002\/cncr.25018","article-title":"Risk factors for fatigue severity in primary brain tumor patients","volume":"116","author":"Armstrong","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.neuropharm.2020.108424_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.11.011","article-title":"Behavioral insights from mouse models of forebrain--and amygdala-specific glucocorticoid receptor genetic disruption","volume":"336","author":"Arnett","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib9","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1038\/tp.2015.35","article-title":"The role of glucocorticoid receptor-dependent activity in the amygdala central nucleus and reversibility of early-life stress programmed behavior","volume":"5","author":"Arnett","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108424_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1215\/15228517-2007-057","article-title":"Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors","volume":"10","author":"Arnold","year":"2008","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neuroscience.2013.01.074","article-title":"Stress effects on BDNF expression: effects of age, sex, and form of stress","volume":"239","author":"Bath","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108424_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0140-6736(03)12328-8","article-title":"Primary brain tumours in adults","volume":"361","author":"Behin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108424_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF02251279","article-title":"BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties","volume":"110","author":"Blackburn","year":"1993","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2020.108424_bib14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/NDT.S65874","article-title":"Psychiatric symptoms in glioma patients: from diagnosis to management","volume":"11","author":"Boele","year":"2015","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2020.108424_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2012.11.003","article-title":"Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex","volume":"67","author":"Cambiaghi","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108424_bib16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/annonc\/mdq458","article-title":"Cancer-related fatigue: a practical review","volume":"22","author":"Campos","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0169-328X(94)90099-X","article-title":"Glucocorticoids and the expression of mRNAs for neurotrophins, their receptors and GAP-43 in the rat hippocampus","volume":"26","author":"Chao","year":"1994","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib19","doi-asserted-by":"crossref","first-page":"25485","DOI":"10.1074\/jbc.M501707200","article-title":"Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase","volume":"280","author":"Chiang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108424_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pnpbp.2012.05.018","article-title":"Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex","volume":"39","author":"Chiba","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108424_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4161\/oxim.3.6.14787","article-title":"Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders","volume":"3","author":"Chong","year":"2010","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.neuropharm.2020.108424_bib22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neubiorev.2008.09.001","article-title":"Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates","volume":"33","author":"Cirulli","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2020.108424_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.brainresbull.2008.03.005","article-title":"Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders","volume":"76","author":"Cleary","year":"2008","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2020.108424_bib87","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1126\/science.1124147","article-title":"Hypothalamic mTOR signaling regulates food intake","volume":"312","author":"Cota","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108424_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0006-8993(98)01258-X","article-title":"Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests","volume":"835","author":"Crawley","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108424_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0889-1591(02)00002-8","article-title":"Cytokines and depression: an update","volume":"16","author":"Dantzer","year":"2002","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2020.108424_bib28","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1111\/j.1476-5381.2011.01716.x","article-title":"Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats","volume":"165","author":"Deblon","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib29","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.biopsych.2006.02.013","article-title":"A neurotrophic model for stress-related mood disorders","volume":"59","author":"Duman","year":"2006","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108424_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuropharm.2012.05.015","article-title":"From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches","volume":"68","author":"Ehninger","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108424_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbr.2012.12.060","article-title":"Differential effects of subchronic phencyclidine on anxiety in the light-enhanced startle-, light\/dark exploration- and open field tests","volume":"243","author":"Enkel","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nbd.2006.12.003","article-title":"Rapamycin is a neuroprotective treatment for traumatic brain injury","volume":"26","author":"Erlich","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108424_bib33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.2044-8295.1979.tb01713.x","article-title":"Emotionality in male and female rodents: a reply to Archer","volume":"70","author":"Gray","year":"1979","journal-title":"Br. J. Psychol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neuroscience.2012.08.034","article-title":"Dynamic plasticity: the role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors","volume":"239","author":"Gray","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108424_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2020.108424_bib36","doi-asserted-by":"crossref","first-page":"pe24","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition","volume":"2","author":"Guertin","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neuropharm.2020.108424_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2014.06.056","article-title":"Acute systemic rapamycin induces neurobehavioral alterations in rats","volume":"273","author":"Hadamitzky","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyy017","article-title":"Repeated systemic treatment with rapamycin affects behavior and amygdala protein expression in rats","author":"Hadamitzky","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib39","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2020.108424_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0149-7634(88)80004-6","article-title":"Biological basis of the behavior of sick animals","volume":"12","author":"Hart","year":"1988","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2020.108424_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093691","article-title":"Single rapamycin administration induces prolonged downward shift in defended body weight in rats","volume":"9","author":"Hebert","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2020.108424_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00006842-199307000-00004","article-title":"Stress and immunity in humans: a meta-analytic review","volume":"55","author":"Herbert","year":"1993","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.neuropharm.2020.108424_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2010.05.024","article-title":"Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy","volume":"40","author":"Huang","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108424_bib44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.brainres.2006.06.077","article-title":"Chronic corticosterone decreases brain-derived neurotrophic factor (BDNF) mRNA and protein in the hippocampus, but not in the frontal cortex, of the rat","volume":"1110","author":"Jacobsen","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib45","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1016\/j.transproceed.2009.08.050","article-title":"Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement","volume":"41","author":"Lang","year":"2009","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.neuropharm.2020.108424_bib46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbr.2008.03.024","article-title":"Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice","volume":"191","author":"Lau","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib47","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jid.2018.02.045","article-title":"Rapamycin modulates glucocorticoid receptor function, blocks atrophogene REDD1, and protects skin from steroid atrophy","volume":"138","author":"Lesovaya","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib48","article-title":"Effect of chronic administration of low dose rapamycin on development and immunity in young rats","volume":"10","author":"Lu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2020.108424_bib49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbi.2019.04.013","article-title":"Behavioral conditioning of anti-proliferative and immunosuppressive properties of the mTOR inhibitor rapamycin","volume":"79","author":"L\u00fcckemann","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2020.108424_bib50","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1158\/1078-0432.CCR-08-2342","article-title":"Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide","volume":"15","author":"Lun","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1741-7015-10-66","article-title":"Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways","volume":"10","author":"Maes","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.neuropharm.2020.108424_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archpsyc.1995.03950140007002","article-title":"Depression in patients with cancer. Diagnosis, biology, and treatment","volume":"52","author":"McDaniel","year":"1995","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108424_bib53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0959-4388(95)80028-X","article-title":"Stress and cognitive function","volume":"5","author":"McEwen","year":"1995","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000445875","article-title":"Rapid down-regulation of glucocorticoid receptor gene expression in the dentate gyrus after acute stress in vivo: role of DNA methylation and MicroRNA activity","volume":"104","author":"Mifsud","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.neuropharm.2020.108424_bib55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fnbeh.2017.00101","article-title":"The evidence for altered BDNF expression in the brain of rats reared or housed in social isolation: a systematic review","volume":"11","author":"Mur\u00ednov\u00e1","year":"2017","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108424_bib56","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2174\/157015911798376262","article-title":"Neurotrophins role in depression neurobiology: a review of basic and clinical evidence","volume":"9","author":"Neto","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neuroscience.2012.09.073","article-title":"Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system","volume":"239","author":"Numakawa","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108424_bib58","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.mp.4002148","article-title":"Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice","volume":"14","author":"O'Connor","year":"2009","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108424_bib59","doi-asserted-by":"crossref","first-page":"12977","DOI":"10.1523\/JNEUROSCI.4209-06.2006","article-title":"Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons","volume":"26","author":"Parsons","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108424_bib60","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.neuropharm.2020.108424_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0149-7634(85)90032-6","article-title":"Can drug effects on anxiety and convulsions be separated?","volume":"9","author":"Pellow","year":"1985","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2020.108424_bib62","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","article-title":"The mTOR signalling pathway in human cancer","volume":"13","author":"P\u00f3pulo","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108424_bib63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1515\/REVNEURO.2000.11.1.53","article-title":"Animal models of depression: utility for transgenic research","volume":"11","author":"Porsolt","year":"2000","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108424_bib64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neures.2010.06.008","article-title":"Activation of mammalian target of rapamycin signaling in spatial learning","volume":"68","author":"Qi","year":"2010","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib65","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib66","first-page":"21","article-title":"Power comparisons of shapiro-wilk, Kolmogorov-smirnov, lilliefors and anderson-darling tests","volume":"2","author":"Razali","year":"2011","journal-title":"J. Statist. Model. Anal."},{"key":"10.1016\/j.neuropharm.2020.108424_bib67","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1073\/pnas.0337480100","article-title":"The hippocampus mediates glucocorticoid-induced impairment of spatial memory retrieval: dependence on the basolateral amygdala","volume":"100","author":"Roozendaal","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108424_bib68","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12035-012-8314-5","article-title":"The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis","volume":"46","author":"Russo","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082226","article-title":"mTOR-related brain dysfunctions in neuropsychiatric disorders","volume":"19","author":"Ryskalin","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108424_bib70","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1073\/pnas.81.19.6174","article-title":"Glucocorticoid-sensitive hippocampal neurons are involved in terminating the adrenocortical stress response","volume":"81","author":"Sapolsky","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108424_bib71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neuropharm.2020.108424_bib72","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.93.24.13780","article-title":"TOR2 is required for organization of the actin cytoskeleton in yeast","volume":"93","author":"Schmidt","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108424_bib73","doi-asserted-by":"crossref","first-page":"7s","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.neuropharm.2020.108424_bib74","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7164\/antibiotics.28.727","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization","volume":"28","author":"Sehgal","year":"1975","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.neuropharm.2020.108424_bib75","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1038\/npp.2012.131","article-title":"PI3K\/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3","volume":"37","author":"Shi","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108424_bib76","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1210\/endo.136.9.7649080","article-title":"Stress increases brain-derived neurotropic factor messenger ribonucleic acid in the hypothalamus and pituitary","volume":"136","author":"Smith","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2020.108424_bib77","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/mp.2017.144","article-title":"BDNF at the synapse: why location matters","volume":"22","author":"Song","year":"2017","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108424_bib78","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbr.2011.02.021","article-title":"Favoured genetic background for testing anxiolytics in the fear-potentiated and light-enhanced startle paradigms in the rat","volume":"221","author":"Steiner","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108424_bib79","article-title":"mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?","author":"Sun","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.neuropharm.2020.108424_bib80","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/1440-1681.12601","article-title":"Anorexic response to rapamycin does not appear to involve a central mechanism","volume":"43","author":"Toklu","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/12703","article-title":"Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety","volume":"23","author":"Tronche","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2020.108424_bib82","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10519-012-9571-9","article-title":"Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL\/6 mice","volume":"43","author":"Tsai","year":"2013","journal-title":"Behav. Genet."},{"key":"10.1016\/j.neuropharm.2020.108424_bib83","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/neuonc\/nou127","article-title":"Prevalence and predictors of fatigue in glioblastoma: a prospective study","volume":"17","author":"Valko","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neuropharm.2020.108424_bib84","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"V\u00e9zina","year":"1975","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.neuropharm.2020.108424_bib85","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1073\/pnas.0402208101","article-title":"Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability","volume":"101","author":"Wei","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108424_bib86","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/neuonc\/nox115","article-title":"Neurological complications of new chemotherapy agents","volume":"20","author":"Zukas","year":"2018","journal-title":"Neuro Oncol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:50:25Z","timestamp":1777431025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820304925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":87,"alternative-id":["S0028390820304925"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108424","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor rapamycin","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108424"}}